Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 5202 | 1187594-09-7 |
Dose | Unit | Route |
---|---|---|
4 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
May 31, 2018 | FDA | ELI LILLY AND CO | |
July 3, 2017 | PMDA | Eli Lilly Japan KK | |
Feb. 13, 2017 | EMA | Eli Lilly Nederland B.V. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Therapy interrupted | 71.08 | 25.33 | 23 | 1682 | 10768 | 46673589 |
Therapy cessation | 70.66 | 25.33 | 29 | 1676 | 26600 | 46657757 |
COVID-19 | 66.03 | 25.33 | 25 | 1680 | 18550 | 46665807 |
Tooth dislocation | 45.66 | 25.33 | 6 | 1699 | 24 | 46684333 |
Herpes zoster | 35.41 | 25.33 | 25 | 1680 | 67847 | 46616510 |
Pneumonia haemophilus | 33.87 | 25.33 | 7 | 1698 | 554 | 46683803 |
Ovarian adenoma | 32.62 | 25.33 | 6 | 1699 | 258 | 46684099 |
Tubular breast carcinoma | 27.11 | 25.33 | 4 | 1701 | 42 | 46684315 |
COVID-19 pneumonia | 25.76 | 25.33 | 8 | 1697 | 3267 | 46681090 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | L04AA37 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
FDA MoA | N0000190857 | Janus Kinase Inhibitors |
FDA EPC | N0000190858 | Janus Kinase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
Coronavirus infection | off-label use | 186747009 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.49 | acidic |
pKa2 | 4.6 | Basic |
pKa3 | 1.9 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
2MG | OLUMIANT | ELI LILLY AND CO | N207924 | May 31, 2018 | RX | TABLET | ORAL | May 31, 2023 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase JAK1 | Kinase | INHIBITOR | IC50 | 8.23 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Tyrosine-protein kinase JAK2 | Kinase | INHIBITOR | IC50 | 8.24 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Non-receptor tyrosine-protein kinase TYK2 | Kinase | INHIBITOR | IC50 | 7.28 | SCIENTIFIC LITERATURE | ||||
Tyrosine-protein kinase JAK3 | Kinase | IC50 | 6.10 | CHEMBL |
ID | Source |
---|---|
ISP4442I3Y | UNII |
4037600 | VANDF |
C4044947 | UMLSCUI |
3JW | PDB_CHEM_ID |
CHEMBL2105759 | ChEMBL_ID |
DB11817 | DRUGBANK_ID |
D10308 | KEGG_DRUG |
44205240 | PUBCHEM_CID |
9570 | INN_ID |
C000596027 | MESH_SUPPLEMENTAL_RECORD_UI |
7792 | IUPHAR_LIGAND_ID |
2047232 | RXNORM |
256448 | MMSL |
32650 | MMSL |
d08568 | MMSL |
017220 | NDDF |
726518002 | SNOMEDCT_US |
763701005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Olumiant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-4182 | TABLET, FILM COATED | 2 mg | ORAL | NDA | 33 sections |
Olumiant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-4732 | TABLET, FILM COATED | 1 mg | ORAL | NDA | 33 sections |